Skip to main content
Premium Trial:

Request an Annual Quote

Variagenics Q4 Revenues Up on Commericialization of Genotyping Systems

NEW YORK, Feb 15 – Variagenics said Thursday its fourth-quarter revenues jumped to $1.2 million, compared with $100,000 in the previous year while revenues for the year rose to $2.3 million from $400,000.

"The year 2000 was pivotal for Variagenics as we commercialized our proprietary technologies for identifying drug-specific genetic markers," Taylor Crouch, CEO of Variagenics, said in a statement. "We are pursuing a vision to place Variagenics' pharmacogenomics at the heart of a new generation of individualized drugs and companion diagnostics.”

Fourth-quarter net losses excluding non-cash equity compensation was $1.8 million, or eight cents a diluted share, compared with $2.3 million, or $3.20 a diluted share, in the year ago period.

For the year, net losses excluding non-cash equity compensation totaled $9.2 million, or 85 cents a diluted share, compared with $13.7 million, or $22.65 a diluted share, in 1999.

The company ended the year with $99.0 million in cash and marketable securities.

During the year, Variagenics of Cambridge, Mass., launched a custom DNA analysis platform, known as NuCleave, and licensed its first system to Covance Central Laboratories Services. The system combines Variagenics' chemical cleavage genotypying and haplotying technologies, Bruker Daltonics' mass spectrometry, Hamilton's robotics, and Waters' DNA sample purification technology.

Waters gave Variagenics $3.0 million in cash in July and made an equity investment in the company for $7.5 million in common stock. Variagenics received a milestone payment from Waters following the sale of the NuCleave system to Covance.

In 2000, the company also expanded its genetic marker database for use in the drug discovery process. The company has patent filings on some 30,000 genetic markers.

So far in 2001, Variagenics has announced deals with Amgen and Isis Pharmaceuticals.

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.